Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

27.84 -0.25 (-0.91%)
Streaming Delayed Price Updated: 3:07 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
99 100 Next >
7 Value Stocks to Buy and Hold for a Decade of Dominance
Discover the enduring value of seven key value stocks to buy and hold in diverse sectors, presenting unparalleled opportunities. 
Via InvestorPlace
Could Novavax Become the Next Moderna?
Sanofi believes in Novavax's vaccine strengths... 
Via The Motley Fool
Which Is The Best Investment For You? High Yield Pfizer Or Higher Growth Merck?
It depends on what your goals, objectives, and risk tolerances are. 
Via Talk Markets
Spotlight on Pfizer: Analyzing the Surge in Options Activity
Via Benzinga
2 Top Growth Stocks Down 24% and 50% to Buy With $100
Investors might be remiss to overlook these stocks. 
Via The Motley Fool
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France,... 
Via Benzinga
Is This a Setback for Moderna?
Moderna's shares slipped after the company announced the delay. 
Via The Motley Fool
2 Beaten-Down Stocks to Buy and Hold for 10 Years
They offer plenty of upside and solid dividend growth. 
Via The Motley Fool
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
AI continues to impact pharma stocks to buy in a major way, with these shares particularly well positioned as things heat up. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics. 
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
From Arvinas Inc.
Via GlobeNewswire
Pfizer Settles Zantac Lawsuits, Agrees To $250M Settlement To Reduce Liability: Report
In a bid to settle thousands of lawsuits over its discontinued heartburn drug Zantac, Pfizer Inc has agreed to pay up to $250 million. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Pfizer, Freeport-McMoRan, Vertex Pharmaceuticals And A Major Tech Stock On CNBC's 'Final Trades'
Pfizer is looking to build on the success of its COVID-19 vaccine rollout by introducing a direct-to-consumer medicines platform. 
Via Benzinga
Exposures COVID-19
7 Cheap Value Stocks to Buy Now: May 2024
Worried about a potential market correction? These seven cheap value stocks are bargains today regardless of the broader economic climate. 
Via InvestorPlace
3 No-Brainer Stocks to Buy With $500 Right Now
A modest amount of money can go a long way on Wall Street when it's put to work in game-changing companies. 
Via The Motley Fool
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
2 Healthcare Stocks to Buy and Hold for Great Long-Term Potential
These healthcare stocks offer completely different approaches to long-term investment gains. 
Via The Motley Fool
Pfizer Follows Eli Lilly's Footsteps To Sell Medicines Directly To Patients
Pfizer seeks to expands its reach with 'Pfizer for All,' offering direct-to-consumer medical services, including COVID treatments & telehealth. 
Via Benzinga
Exposures COVID-19
Healthcare Giants Pfizer, AstraZeneca, Sanofi Inject Over $2B To Boost France's Healthcare Sector
Pfizer and AstraZeneca invest over $1 billion in France's healthcare sector, bolstering R&D capabilities and job creation. 
Via Benzinga
How Viking Therapeutics Stock Could 30x
This mid-cap biopharma may one day be a titan of the industry. 
Via The Motley Fool
3 Stocks That Suddenly Drew in Options Traders
Three discounted stocks caught the attention of call option buyers last week, and they have Wall Street analysts to back them through double-digit upside. 
Via MarketBeat
Generis Welcomes Max Kelleher as New Chief Executive Officer
LONDON - May 14, 2024 - PRLog -- Generis, creator of the cloud data, content, and business process management platform CARA™, today announced that Max Kelleher will be stepping into the role of Chief... 
Via PRLog
Want $1,000 in Dividend Income? Here's How Much You'd Have to Invest in Pfizer Stock
Pfizer stock currently has a 5.9% dividend yield, making it an attractive target for income investors. 
Via The Motley Fool
'Seems Low:' Elon Musk Questions Pfizer's $0 Tax Bill, But Did Tesla Pony Up To Uncle Sam?
In December 2021, Musk paid a record-breaking $11 billion in federal income taxes, resulting from selling Tesla stock to finance his purchase of Twitter. 
Via Benzinga
Earn $1000 Every Month From These 3 Stocks
All 3 companies pay growing dividends. 
Via The Motley Fool
Top Stock Reports For Amazon.com, Visa & Pfizer
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc., Visa Inc.. and Pfizer Inc. 
Via Talk Markets
The 10 Worst Performing S&P 500 Stocks in 2023 - Are They Good Investments Now?
A look at the 10 worst-performing S&P 500 stocks in 2023. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Stocks Surge On Healthy Earnings Season, Rising Jobless Claims: This Week In The Markets
Week in markets: quiet week, Q1 earnings positive, S&P 500 and Dow Jones up, utilities sector stands out, job market and inflation concerns, interest rate cuts expected. Buffett reduces Apple stake,... 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
FDA Delays 'Important' Moderna Vaccine Review: William Blair Says 2025 Growth, '2026 Breakeven Story' Depends On It
FDA update: Moderna's BLA for mRNA-1345, RSV vaccine, may face delay past May 12 deadline. But no safety concerns reported. 
Via Benzinga
Exposures Product Safety
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.